MaxCyte, Inc. (MXCT)

Market Cap	248.60M
Revenue (ttm)	37.68M
Net Income (ttm)	-41.79M
Shares Out	106.32M
EPS (ttm)	-0.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	634,895
Open	2.420
Previous Close	2.355
Day's Range	2.230 - 2.469
52-Week Range	2.210 - 5.260
Beta	1.21
Analysts	Strong Buy
Price Target	9.00 (+289.61%)
Earnings Date	May 7, 2025

About MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineer...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 114
• Stock Exchange: NASDAQ
• Ticker Symbol: MXCT
• Website: https://www.maxcyte.com

Financial Performance

In 2024, MaxCyte's revenue was $38.63 million, a decrease of -6.44% compared to the previous year's $41.29 million. Losses were -$41.06 million, 8.26% more than in 2023.

Analyst Forecast

According to one analyst, the rating for MXCT stock is "Strong Buy" and the 12-month stock price forecast is $9.0.

Price Target

$9.0

(289.61% upside)

Analyst Consensus: Strong Buy